{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:43:25Z","timestamp":1790462605405,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Effective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). This trial aims to evaluate sofosbuvir and daclatasvir versus standard care for outpatients with mild COVID-19 infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a randomized controlled clinical trial in outpatients with mild COVID-19. Patients were randomized into a treatment arm receiving sofosbuvir\/daclatasvir plus hydroxychloroquine or a control arm receiving hydroxychloroquine alone. The primary endpoint of the trial was symptom alleviation after 7\u2009days of follow-up. The secondary endpoint of the trial was hospital admission. Fatigue, dyspnoea and loss of appetite were investigated after 1\u2009month of follow-up. This study is registered with the IRCT.ir under registration number IRCT20200403046926N1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 8 April 2020 and 19 May 2020, 55 patients were recruited and allocated to either the sofosbuvir\/daclatasvir treatment arm (n\u2009=\u200927) or the control arm (n\u2009=\u200928). Baseline characteristics were similar across treatment arms. There was no significant difference in symptoms at Day 7. One patient was admitted to hospital in the sofosbuvir\/daclatasvir arm and four in the control arm, but the difference was not significant. After 1\u2009month of follow-up, two patients reported fatigue in the sofosbuvir\/daclatasvir arm and 16 in the control arm; P\u2009&amp;lt;\u20090.001.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, sofosbuvir\/daclatasvir did not significantly alleviate symptoms after 7\u2009days of treatment compared with control. Although fewer hospitalizations were observed in the sofosbuvir\/daclatasvir arm, this was not statistically significant. Sofosbuvir\/daclatasvir significantly reduced the number of patients with fatigue and dyspnoea after 1\u2009month. Larger, well-designed trials are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa501","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:21:17Z","timestamp":1605241277000},"page":"753-757","source":"Crossref","is-referenced-by-count":52,"title":["Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial"],"prefix":"10.1093","volume":"76","author":[{"given":"Fatemeh","family":"Roozbeh","sequence":"first","affiliation":[{"name":"Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Saeedi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Hedayatizadeh-Omran","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-6723","authenticated-orcid":false,"given":"Shahin","family":"Merat","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wentzel","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Levi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Homerton University Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-0209","authenticated-orcid":false,"given":"Amir","family":"Shamshirian","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran"},{"name":"Department of Medical Laboratory Sciences, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"2021021208592693800_dkaa501-B1","year":"2020"},{"key":"2021021208592693800_dkaa501-B2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/cid\/ciz628","article-title":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial","volume":"70","author":"Merat","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021021208592693800_dkaa501-B3","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1038\/s41598-020-66440-9","article-title":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic","volume":"10","author":"Jacome","year":"2020","journal-title":"Sci Rep"},{"key":"2021021208592693800_dkaa501-B4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"2021021208592693800_dkaa501-B5","article-title":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","author":"Sacramento","year":"2020","journal-title":"bioRxiv"},{"key":"2021021208592693800_dkaa501-B6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"2021021208592693800_dkaa501-B7","first-page":"767","article-title":"Rapid Review Neurological associations of COVID-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Glob Heal"},{"key":"2021021208592693800_dkaa501-B8","article-title":"Sofosbuvir protects human brain organoids against SARS-CoV-2","author":"Mesci","year":"2020","journal-title":"bioRxiv"},{"key":"2021021208592693800_dkaa501-B9","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","article-title":"The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19","volume":"75","author":"Eslami","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021208592693800_dkaa501-B10","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021208592693800_dkaa501-B11","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021208592693800_dkaa501-B12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2055-6640(20)30018-2","article-title":"Minimum costs to manufacture new treatments for COVID-19","volume":"6","author":"Hill","year":"2020","journal-title":"J Virus Erad"},{"key":"2021021208592693800_dkaa501-B13","doi-asserted-by":"crossref","first-page":"e102324","DOI":"10.5812\/iranjradiol.102324","article-title":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)","volume":"17","author":"Mahdavi","year":"2020","journal-title":"Iran J Radiol"},{"key":"2021021208592693800_dkaa501-B14","year":"2020"},{"key":"2021021208592693800_dkaa501-B15","year":"2020"},{"key":"2021021208592693800_dkaa501-B16","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/jac\/dkaa171","article-title":"Favipiravir, an antiviral for COVID-19?","volume":"75","author":"Coomes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021021208592693800_dkaa501-B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"2021021208592693800_dkaa501-B18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021208592693800_dkaa501-B19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2021021208592693800_dkaa501-B20","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021208592693800_dkaa501-B21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021208592693800_dkaa501-B22","article-title":"Effect of Dexamethasone in Hospitalized Patients with COVID-19: preliminary Report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021208592693800_dkaa501-B23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/jgh.14994","article-title":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","volume":"35","author":"Poustchi","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2021021208592693800_dkaa501-B24","first-page":"e44564","article-title":"The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3","volume":"17","author":"Merat","year":"2017","journal-title":"Hepat Mon"},{"key":"2021021208592693800_dkaa501-B25","author":"Aylward","year":"2020"},{"key":"2021021208592693800_dkaa501-B26","author":"Devlin","year":"2020"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/753\/36241025\/dkaa501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/753\/36241025\/dkaa501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:32:27Z","timestamp":1613176347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/753\/6041772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,18]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa501","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,18]]}}}